Douglas Edward Gladstone MD

System Chief, Hematology and Hematologic Oncology. Professor, Zucker School of Medicine at Hofstra/Northwell

450 Lakeville RoadLake Success, NY 11042
Phone+1 516-734-8900
Fax+1 516-734-7626

Dr. Gladstone is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gladstone's full profile Already have an account?

Summary

Dr. Douglas Gladstone is an oncologist based in Lake Success, NY, currently serving as the System Chief of Hematology and Hematologic Oncology at Northwell Health. He completed his fellowship in Hematology and Medical Oncology at Johns Hopkins University and holds a medical degree from New York University School of Medicine. His experience spans cancer-associated retinopathy, hematologic oncology, bone marrow transplantation, acute myeloid leukemia, and Hodgkin's lymphoma. Dr. Gladstone has held notable academic positions at Johns Hopkins University School of Medicine. His recent publications focus on BTK inhibition in leukemia, COVID-19 therapies, and treatments for B-cell malignancies. Additionally, he has been actively involved in clinical trials related to immune system and cancer research, and he received the CMS Meaningful Use Stage 1 Certification from Epic Systems in 2013-2014.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1996 - 1999
University of Rochester Medical CenterResidency, Internal Medicine, 1992 - 1996
New York University School of MedicineClass of 1992

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 1993 - 2028
MD State Medical License 1996 - 2022
NC State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
PA State Medical License 1999 - 2004

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
WITHDRAWN
PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies Start of enrollment: 2014 Mar 13
COMPLETED
PHASE1, PHASE2
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies Start of enrollment: 2018 Jul 31
TERMINATED
PHASE1

Publications & Presentations

PubMed

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.
Clive S Zent, Enrico Tiacci, Robert J Kreitman, Tamar Tadmor, Martin S Tallman
Blood. 2026-07-02
Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies.
Pratik Vijay Shah, Anita Ng, Andrew Shih, Tony Pham, Justin Wang
Journal of Personalized Medicine. 2026-05-22
Early Discharge Clinic: A Quality Improvement Initiative to Create a Safe and Efficient Model for Intensive Outpatient Management of Hematologic Malignancies.
Christina A Mallilo, Brittany Mockler, Joo Yeon Seo, Monica Wallin, Douglas E Gladstone
JCO Oncology Practice. 2026-05-19

Abstracts/Posters

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis
Douglas E Gladstone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients
Douglas E Gladstone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
Douglas E Gladstone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Cytomegalovirus Reactivation in Haploidentical Blood or Marrow Transplant (BMT) Using Post-Transplant Cyclophosphamide (PTCy) Is Associated with Higher Non-Relapse-Rel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018